The Retinoblastoma 1 (RB1) tumor suppressor, a member of the Retinoblastoma gene family, functions as a pocket protein for the functional binding of E2F transcription factors. About 1/3 of retinoblastoma patients harbor a germline RB1 mutation or deletion, leading to the development of retinoblastoma. Here, we demonstrate generation of a heterozygous deletion of the RB1 gene in the H1 human embryonic stem cell line using CRISPR/Cas9 nickase genome editing. The RB1
Resource

Resource utility
We generate a human embryonic stem cell (hESC) line with heterozygous RB1 deletion to facilitate the modeling of the cancer etiology of hereditary retinoblastoma.
Resource details
Hereditary retinoblastoma patients commonly carry a heterozygous RB1 mutation or deletion (Lin et al., 2017) . Random sporadic damage to the remaining normal copy of RB1 in retinal cells initiates development of retinoblastoma. To provide a useful lab resource for scientists investigating hereditary retinoblastoma, we generated a heterozygous RB1 deletion hESC line by targeting exon 16 of the RB1 gene using the CRISPR/Cas9 nickase gene editing system (Fig. 1A , the Cas9/sgRNA target sites are underlined and RB1 introns and exons are presented in lowercase and uppercase, respectively).
hESC H1 cells were transfected with pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A) (Puro R ) plasmids carrying sgRNAs targeting exon 16 of the RB1 gene. Electroporated cells were selected by puromycin. The puromycin-resistant clones were picked up, isolated, and expanded. The RB1 targeted regions were analyzed by PCR to demonstrate that only one allele was deleted (Fig. 1B) . Primers surrounding exon 16 (amplifying both the wild-type and deleted alleles) were designed and the genetic region amplified by PCR and examined by Sanger sequencing. The mono-allelic 50-nucleotide-deletion was confirmed in the deleted allele, while the other allele retained its wild-type sequence (Fig. 1C) . A premature stop codon was also noted in RB1 exon 17 in the allele with a 50-nucleotide-deletion in one of two heterozygous RB1 deletion hESC clones obtained and submitted for further characterization.
The H1-RB1(E16) −/+ line maintains a classical tightly packaged dome-shape hESC morphology and expresses high levels of pluripotency transcription factors (NANOG and OCT4), hESC surface markers (SSEA4 and TRA-1-81) as well as alkaline phosphatase (AP) (Fig. 1D , scale bar 100 μm). The expression of pluripotency genes (NANOG, OCT4, SOX2, DPPA4, and REX1) in the H1-RB1(E16) −/+ line was compared to the levels in parental H1 cells by quantitative real-time PCR. PCR reactions are normalized to GAPDH. The expression levels of all five pluripotency genes in the H1-RB1(E16) −/+ line were comparable to those in parental H1 cells (Fig. 1E , error bars indicate ± SEM of triplicates).
Immunoblotting results suggested that RB1 expression is lower in the H1-RB1(E16) −/+ line than in parental H1 cells (Fig. 1F) . PCR-based mycoplasma detection assay confirmed the cell line is mycoplasma-free ( Fig. 1G ). Karyotype analysis suggested that the H1-RB1(E16) −/+ line does not contain any chromosomal abnormality ( Fig. 1H) . Additionally, the short tandem repeat (STR) profile of H1-RB1(E16) −/+ cells was identical to that of their parental H1 cells (Supplementary Table S1 ). Furthermore, H1-RB1 (E16) −/+ cells maintained the potential to differentiate into all three germ layers as determined by their ability to differentiate to SOX17 and HNF4A-positive hepatic progenitor cells (HPCs, endodermal lineage) ( 
Materials and methods
Maintenance of hESCs
hESCs were maintained on Matrigel (Corning)-coated plates with StemMACS ™ iPS-Brew XF (Miltenyi Biotec). StemMACS ™ Passaging Solution XF (Miltenyi Biotec) was used to passage hESCs and Rock inhibitor (Calbiochem) was utilized to improve cell survival rate during replating.
Generation of RB1 heterozygous deletion hESC line by CRIPSR/Cas9 nickase gene editing methodology
A CRISPR guide targeting exon 16 of RB1 was designed using CRISPR Design website (http://crispr.mit.edu). Two sgRNAs (TTAGCAAACTTCTGAGTGAC and TTTATTGGCGTGCGCTCTTG) targeting exon 16 of RB1 gene were selected and cloned into pX335-U6-Chimeric_BB-CBh-hSpCas9n(D10A)(Puro R ), respectively to generate the guide plasmids. For electroporation, 10 7 cells were re-suspended with 0.6 ml Embryo Max Electroporation Buffer (Millipore), mixed with CRISPR/Cas9 nickase plasmids (25 μg each) and electroporated at 300 V/500 μF in a BIO-RAD Gene Pulser Xcell System. Following electroporation, cells were immediately dispensed into 10 cm MEF-coated plates in hESC medium (DMEM/F12 (Corning) with 20% KnockOut Serum replacement (Life Technologies), 1% Gibco GlutaMax (Life Technologies), 1% NEAA (Corning), 0.0007% β-mercaptoethanol (Sigma) and 10 ng/ml FGF2 (EMD Millipore)) supplemented with 10 μM ROCK inhibitor. After 48 h recovery, cells were treated with 1 μM puromycin (Sigma) for 48 h and then maintained in regular hESC medium for colony growth. The isolated genomic DNA from individual colonies was used for clonal identification by PCR using a RB1 exon 16 specific primer set (forward: 5′-TCTGTTTCAGGAAGAAGAACGAT-3′; reverse: 5′-ACCATGGAGGTTACAGCAGTG-3′). The PCR fragments of wild-type and deletion of RB1 exon 16 were examined by Sanger sequencing.
Quantitative real-time PCR
Total mRNA was isolated using TRIzol (Invitrogen) following the manufacturer's instructions. 1 μg of RNA was used for reverse transcription. Real-time PCR analysis was performed on a CFX96 machine (Bio-Rad) using the SYBR Green PCR Master Mix (BioRad). The PCR reaction consisted of 10 μl SYBR Green PCR Master Mix, 1 μl of 10 μM forward and reverse primers, and 1 μl of 3-times diluted template cDNA in a total volume of 20 μl. Samples were analyzed in triplicate and normalized to GAPDH expression. The primer sequences are shown in Table 1 .
In vitro differentiation
In vitro differentiation of H1-RB1(E16) −/+ cells to HPCs, MSCs, and NPCs was performed by well-defined differentiation protocols described previously (Chambers et al., 2009; Qin et al., 2016; Zhao et al., 2015) . For cell characterization, SOX17 (R&D Systems) and HNF4A (Cell Signaling Technology) were used for HPCs, CD105 (Thermo Fisher Scientific) and CD73 (BD Biosciences) were used for MSCs, and PAX6 (BioLegend) and NESTIN (BioLegend) were used for NPCs.
Immunofluorescent staining and immunoblotting
H1-RB1(E16) −/+ cells or differentiated cells were fixed with 4% paraformaldehyde in PBS for 10 min at room temperature, blocked with 10% serum in 0.1% PBST for 1 h and incubated with the indicated primary antibodies (Table 2) overnight. Cells were then washed with PBST, incubated with corresponding secondary antibodies for 1 h at room temperature, and detected by Leica DMi8. Immunoblotting was performed as described (Lee et al., 2007) .
Mycoplasma test
PCR mycoplasma test kit was used according to the manufacturer's instructions (abm G238).
Karyotype analysis and STR analysis
The G-banding karyotype was performed by The T. C. Hsu Molecular Cytogenetics Facility in The University of Texas M.D. Anderson Cancer Center. Twenty metaphase chromosome spreads were analyzed with G-band resolution of 450-500. STR analysis for parent cell authentication was performed by the Characterized Cell Line Core Facility in The University 
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